|Bid||300.00 x 1200|
|Ask||0.00 x 1100|
|Day's Range||326.89 - 332.23|
|52 Week Range||189.15 - 341.08|
|PE Ratio (TTM)||74.42|
|Earnings Date||Oct 22, 2018 - Oct 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||334.73|
Francis deSouza, Illumina President and CEO, sits down with CNBC's Meg Tirrell in an exclusive CNBC interview to discuss tariffs, business in China, his company earnings and DNA sequencing.
The genome-sequencing company beat quarterly expectations and increased its full-year guidance last month. Here's what investors need to know.
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
Get timely chart analysis and investing lessons on leading stocks that have earned a spot on the IBD 50, an S&P 500-beating screen featuring today's best growth stocks.
China launched a rally across global markets Tuesday, with Etsy, Twilio and Illumina posting early leads in the U.S., as Disney prepared for its report after the close.
The bearish case for Illumina, Inc. (NASDAQ: ILMN ) has come to an end for four key reasons, according to Morgan Stanley. The Analyst Analyst Steve Beuchaw upgraded Illumina from Underweight to Equal-weight ...
DENTSPLY (XRAY) gains from solid year-over-year international revenue growth in Q2; high impairment charges in the quarter mars results.
Cardinal Health (CAH) witnesses strong Q4, owing to strong sales at Pharmaceutical and the Medical segments. It provides an impressive FY19 view.
NEW YORK, Aug. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allete, ...
Investors looking for undervalued stocks in an expensive market should consider equities that are likely to be lifted by big themes that include a growing U.S. economy, expanding U.S. consumer spending, and the increasing use of Big Data, according to Sarat Sehti and Ned Dewees, managing partners of Douglas C. Lane & Associates, as reported by Barron's.
Integer Holdings (ITGR) gains on solid Cardio & Vascular revenues and high organic sales; a solid guidance raises optimism.